Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07650708RecruitingPhase 4
Eye Dryness After LASIK Surgery With a New Dry Eye Treatment
This study tests whether a new eye lubricant called Miebo, given before LASIK vision correction surgery, reduces dry eye symptoms afterward. If you have mild-to-moderate dry eyes and need LASIK, this trial may help you stay more comfortable during your recovery.
Bozeman, MontanaAges 18 years+ - NCT07639944Recruiting
REN Device Study for Jaw Pain and Headaches
This study tests whether a treatment called REN can help reduce headaches and jaw pain caused by temporomandibular disorders (TMD). You would use the REN device at home on your smartphone or tablet over several months.
Newark, DelawareAges 12 years+ - NCT07644832RecruitingPhase 1/Phase 2
New Blood-Clotting Injection for Hemophilia and Factor VII Deficiency
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
ChangshaAges 18–65 - NCT07637162Enrolling by invitationPhase 3
Safety study of AXS-14 for fibromyalgia
This study continues to monitor the safety of an investigational drug called AXS-14 in people with fibromyalgia who previously participated in another AXS-14 trial. Researchers want to make sure the treatment remains safe over time.
Little Rock, ArkansasAges 18 years+ - NCT07627971RecruitingPhase 1/Phase 2
Gene therapy for GJB2-related hearing loss in young children
This study tests an experimental gene therapy (SKY-GJB2) designed to treat hearing loss caused by mutations in the GJB2 gene. The therapy is given directly to children ages 9 months to 7 years who have significant bilateral hearing loss, and researchers will monitor safety and whether hearing improves.
Bethesda, MarylandAges 9 months–7 years - NCT07616687RecruitingPhase 4
Testing guselkumab to improve Crohn's disease control
This study tests whether guselkumab, a newer biologic medication, can better control active Crohn's disease symptoms and inflammation. You'll receive the medication and be monitored closely to see how well it works for you.
AmiensAges 18 years+ - NCT06705296RecruitingPhase 1
Deep brain stimulation for severe PTSD
This trial tests whether deep brain stimulation, a surgery that uses a small device to send electrical pulses to specific brain areas, can help people with severe PTSD that hasn't improved after trying several treatments. It aims to see if this approach is safe and effective for long-lasting symptoms.
Toronto, OntarioAges 18–70 - NCT07610941RecruitingPhase 1
Testing a new cancer drug alone and combined with others
This early-stage trial tests a new experimental drug (MST-0312) in people with solid tumors like lung cancer, melanoma, bladder cancer, colorectal cancer, or triple-negative breast cancer. The goal is to find safe doses and see how well it works, either by itself or paired with other treatments.
BarcelonaAges 18 years+ - NCT07610772RecruitingPhase 1
Safety study of a new hepatitis B antibody for hepatitis D
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
AarhusAges 18–70 - NCT07599592RecruitingEarly Phase 1
Ultrasound Treatment for Essential Tremor
This early-stage study tests whether focused ultrasound waves can safely reduce hand tremors in people with essential tremor. The ultrasound is applied from outside the skin without surgery, and researchers want to see if it helps calm unwanted shaking.
Los Angeles, CaliforniaAges 18–90 - NCT07598578RecruitingEarly Phase 1
New drug combination for hard-to-treat T-cell lymphoma
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) for T-cell lymphomas that have returned or stopped responding to previous treatment. The goal is to see if this combination can help shrink the cancer.
SuzhouAges 18–75 - NCT07593391RecruitingPhase 3
NNZ-2591 Treatment for Children with Phelan-McDermid Syndrome
This study tests whether a medication called NNZ-2591 can help children with Phelan-McDermid syndrome, a rare genetic condition that affects brain development and learning. Researchers want to see if this drug can improve how children with this condition develop and learn.
Birmingham, AlabamaAges 3–12 - NCT07589569RecruitingPhase 2
HRS-7058 for Advanced Pancreatic Cancer Treatment
This study tests a new drug called HRS-7058 in patients with pancreatic cancer that has spread or cannot be removed by surgery. You may qualify if your cancer has already been treated with at least one prior therapy and you have measurable disease on imaging.
Nanjing, JiangsuAges 18–75 - NCT07593820RecruitingPhase 1
CAR-T Cell Study for Advanced HER2-Positive Cancers
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Barcelona, CataloniaAges 18 years+ - NCT06720558Recruiting
Placebo probiotic effects on gut health in mild GI symptoms
This study tests whether a placebo probiotic can improve gut health and overall well-being in people with mild digestive issues like gas, bloating, or irregularity. If you have mild symptoms that don't stop your daily activities, this trial may help understand if believing you're taking a probiotic can make you feel better.
MilanAges 20–65 - NCT07584954RecruitingPhase 1
Testing a new cancer immunotherapy in advanced solid tumors
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Fuzhou, FujianAges 18–75 - NCT07579234RecruitingPhase 3
New drug F182112 for hard-to-treat multiple myeloma
This trial tests a new drug called F182112 against standard treatments for multiple myeloma that has stopped responding to previous therapies. The goal is to see if F182112 works better and is safe for patients whose cancer has become resistant to multiple drug classes.
TianjingAges 18 years+ - NCT07580586RecruitingPhase 1
Study of BV100's effect on polymyxin B in healthy volunteers
This early-stage study tests how a new drug called BV100 affects how your body processes polymyxin B, an antibiotic. Researchers want to understand how these two drugs interact so they can develop safer treatments.
ViennaAges 18–55 - NCT07573631Enrolling by invitationPhase 2
Long-term Safety Study of BMN 351 for Duchenne Muscular Dystrophy
This study continues treatment with an investigational medicine called BMN 351 for people with Duchenne muscular dystrophy (a genetic muscle-weakening condition). It checks whether the medicine remains safe and effective when used over a longer period, building on results from an earlier trial.
Milan, ItalyAges 4 years+ - NCT07570862RecruitingPhase 2
CAR T-Cell Therapy for Hard-to-Treat Lupus Kidney Disease
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
Beverly Hills, CaliforniaAges 12–70 - NCT07568730RecruitingPhase 2
Testing Lacripep eye drops for neurotrophic keratitis
This trial tests whether a new eye drop called Lacripep can help treat neurotrophic keratitis, a rare eye condition where the cornea loses sensation and can become damaged. The study compares Lacripep to a placebo (inactive) drop to see if it improves corneal healing and vision.
Tampa, FloridaAges 18 years+ - NCT06728852RecruitingPhase 2
Vorolanib for advanced lung cancer after other treatments
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06728865RecruitingPhase 2
Furmonertinib plus Avastin for EGFR+ lung cancer with brain mets
This trial tests a combination of two targeted drugs (Furmonertinib and Avastin) as the very first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell) that has spread to the brain. The goal is to see how well it works and how safe it is.
Guangzhou, GuangdongAges 15–75 - NCT07559786RecruitingPhase 2
Adebrelimab after chemo-radiation for limited-stage small cell lung cancer
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
Zhengzhou, HenanAges 18–75
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 366 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.